The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project.

To the Editor, Over the last decades, systematic reviews and meta analyses of multiple double-blind randomized placebo-controlled trials have demonstrated the efficacy and safety of both subcutaneous (SCIT) and sublingual (SLIT) allergen immunotherapy (AIT) for respiratory and insect venom allergy.1 However, there is a wide range of AIT preparations used around the globe, and AEs are not always uniformly recorded, limiting the capability to draw safe conclusions or compare reports. Though various clinical development programs2 have generated substantial knowledge on different AIT preparations, they have been conducted in pre-defined clinical conditions, not reflecting real-life and therefore the results may not have generalized applicability.3 Very few pragmatic trials and observational studies have evaluated AIT safety in real-life. Indicatively, Calderon et al.4 reported a total of 109 systemic reactions (SR) due to AIT recorded in 4316 patients in a prospective, longitudinal, “real-life” web-based survey. Another prospective study5 on SCIT safety in 581 patients reported immediate SR in 2.2%, delayed (7.4%), immediate local reactions (LR) (54.6%), while delayed in 56.1%. Recently, the Respiratory Effectiveness Group highlighted the role of real-world evidence (RWE) in (i) filling knowledge gaps, (ii) extending the implementation of findings from Randomized controlled trials in heterogeneous populations or healthcare systems, and (iii) providing evidence to generate clinical practice guidelines.3 Prospective, systematic RWE from registries are considered to provide a broadly applicable source of knowledge compared with retrospective approaches.6 However, there is still a lack of such registries in the allergy field.7 In this context, a new hierarchy of AIT RWE that ranks pragmatic trials and registry data at the highest level of evidence was proposed in a recent European Academy of Allergy and Clinical Immunology (EAACI) position paper.6 Considering these factors, a Task Force (TF) was created under the academic support of EAACI to develop an AIT Adverse Events Registry (ADER). Adverse Events Registry is a prospective, longitudinal, observational, multicenter, web-based registry of “real-life” AIT clinical practice across multiple countries. It has included centres from eight South-Eastern European countries (Albania, Bulgaria, Croatia, Greece, Romania, Serbia, Slovenia and Turkey) and was academically supported by EAACI through a TF (AIT Adverse Events Registry Task Force). Our framework was based on the previous experience of the European Survey on Adverse Systemic Reactions in Allergen Immunotherapy.8 The TF was chaired by Nikolaos Papadopoulos and led by a Steering Committee (Nikolaos Papadopoulos, Moises Calderon, Ted Popov). The registry team, coordinated by Dimitrios Mitsias, included one to two National Coordinators per country, responsible for following local ethics requirements and recruiting physicians. No fees were provided for participant inclusion. The main objectives of the registry are (I) to assess systemic and local AEs occurring during regular clinical practice in real-life settings, (II) to collect data and evaluate patient characteristics and AIT practice among countries (expected to differ substantially), (III) to identify independent factors associated with AE, and (IV) to use ADER as a model for AIT pharmacovigilance that could be subsequently expanded to other European countries. Based on the EASSI survey e–questionnaires,8 ADER developed three similar questionnaires to collect data (see Supplement). Eligible subjects were adults and children attending regular consultations in real-life clinical settings, presenting symptoms due to IgE mediated respiratory allergies documented by at least one positive skin prick test and/or specific IgE test to a panel of inhalant allergens. Those with verified Hymenoptera Venom Allergy and Venom Immunotherapy (VIT) courses to honey bees, common wasp and/or polistes wasp are also included. All patients are recruited in a prospective manner, on the same day they receive their first dose of a new AIT treatment, either SCIT or SLIT or VIT, and followed up until the end of the course. Systemic and local AEs are registered prospectively. A total of 2772 patients undergoing 3209 immunotherapy courses were retrieved up to May 2017 (Supplementary Table 1). Overall, 1019 systemic and local AEs were recorded in 330 patients. Additional information on the registry is described in the online supplement. Registries are considered a powerful tool that can provide systematic collection of large amounts of data for a long period of treatment. Adverse Events Registry is the first AIT Registry for AE piloted in different countries in Europe that uses the harmonized MedDRA terminology9 (Table 1). These real-life data will generate useful information that complement data from RCTs for decision-making issues for doctors, patients, healthcare providers and policymakers. We aim to expand this Registry to more countries in Europe and possibly worldwide. The questionnaires gather data covering different safety aspects and other characteristics of AIT practice in a pragmatic, low-effort manner. The inclusion of eight different countries leads to substantial heterogeneity (different populations, clinical settings, healthcare systems, AIT products and protocols), providing invaluable information on AIT safety. The registry is designed to collect all possible AEs during the course of a specific AIT in a real-life setting. We are aware that this approach has a few shortcomings, especially in the case of SLIT (which is self-delivered) or LR. However, the study attributes more weight to SR in AIT. In conclusion, we consider ADER as a first effort to create a multinational network of centres practicing AIT and exchanging best practice parameters. We believe this is a step-up in the progress of evidence needed to further support the optimal delivery of AIT. Such complex and factual monitoring may provide robust evidence of safety as well as help us to determine risk factors for AIT related AE. Julijana Asllani: data curation (equal); formal analysis (equal); writing original draft (lead). Dimitrios Mitsias: project administration (lead), methodology (equal), data curation (equal), and formal analysis (equal). George Konstantinou: data curation (equal); formal analysis (equal). Todor A. Popov: conceptualization (equal). Nikolaos G. Papadopoulos: conceptualization (equal); methodology (equal), funding acquisition (lead). Moises Calderon: conceptualization (equal); methodology (equal). All authors: Investigation (equal); writing-review and editing (equal). We acknowledge Mrs Smaragda Vidou for excellent management of the registry. This study was supported by an unrestricted grant from Stallergenes and The EAACI. Open access publishing facilitated by The University of Western Australia, as part of the Wiley - The University of Western Australia agreement via the Council of Australian University Librarians. Julijana Asllani, Alfred Priftanji, Mehmet Hoxha, Gerta Sinani, George Christoff, Dimitrov Zlatko, Michael Makris, Xenofon Aggelidis, Asja Stipic, Diana Deleanu, Vesna Tomic-Spiric, Aleksandra Plavsic, Dilsad Mungan, Mitja Kosnik have no conflicts of interest to declare. Nikolaos G. Papadopoulos has received grants from Capricare, Nestle, Numil, Vianex and/or fees for consultancy from Abbott, Abbvie, Astra Zeneca, GSK, HAL, Medscape, Menarini/Faes Farma, Mylan, Novartis, Nutricia, OM Pharma, Regeneron/Sanofi in the last 3 years. Dimitrios Mitsias is or recently was a speaker for AstraZeneca, Gerolymatos International, Novartis, Sanofi, in the last 3 years. George Konstantinou is or recently was a speaker and/or advisor for and/or has received research funding from AstraZeneca, Chiesi, GSK, Menarini, Novartis, Pfizer, Sanofi, and Vianex in the last 3 years. All other authors do not declare any conflicts of interest. European Academy of Allergy and Clinical Immunology; Stallergenes Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.